Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Https://www.londonstockexchange.com/news-article/POLB/significant-polb-001-patent-granted-in-usa/16448784
https://www.lse.co.uk/rns/immunomodulator-ii-patent-granted-in-japan-cxszu5m4nb6imxx.html
https://www.lse.co.uk/rns/immunomodulator-i-patent-opposition-withdrawal-szhnuwymzudjgng.html
https://www.lse.co.uk/rns/polb-001-patent-portfolio-strengthened-vio3c26hsfx7dr1.html
Polb-001 has reached another major milestone with US Patent granted to add to other Patent protections granted in Asia, Europe etc. Deal for Polb-001 could be signed any day and possible $ multi-million deal. FOMO. The ex Amryt team firing on all cylinders it seems. Hvo has rewarded long term investors well from about 6p to circa 30p. Poolbeg Pharma has been a slow frustrating hold for 3 years but in fairness to Jeremy he has been getting all the ducks in a row. Big investments recently from Cathal, Jeremy and MK etc, some serious stake building appears to have been going on past few weeks at the 12p plus..Great things come to those who wait maybe? JMO Adyor!!!
The trouble with Stt1 (Sickothetech on ADVFN board) he engages his keyboard before his brain, he's got a great investment called Totally, its only down 95%, he's been recommending that for about 7 years...beware! JMO Adyor
I suppose a premium listing would be a waste of time as this is not really a public listed company in normal terms. It seems 65% of the shares are held by a small clic that basically run the company as if it was a private company with little regard to Private Investors. JMO Adyor
Just in case you didn't see Sickothetech's very long post, I thought I'd share it again.
SpuddyMadrid,
That's history.
Look at the newsflow for PTX. There's newsflow in the public domain as to what has been happening with Silk Road Therapeutics, Soligenix's option agreement with Silk Road and phase 2a Behçet's Disease clinical study.
A year ago:
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
"The option agreement grants the Company the right to acquire a novel topical formulation of Pentoxifylline (PTX)"
https://www.prnewswire.com/news-releases/soligenix-enters-into-exclusive-option-agreement-with-silk-road-therapeutics-for-rights-to-topical-pentoxifylline-designed-to-treat-behcets-disease-301811424.html
Only a couple of months ago:
"Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024"
"The initiation of a Phase 2a clinical study in Behçet's Disease later this year will be another important milestone for our company and we look forward to working with the MAB to advance this program."
Comprised of internationally renowned rheumatologists with extensive experience in Behçet's Disease, the MAB will play an important advisory role in the conduct of the upcoming Phase 2a clinical study, as well as in the design of subsequent clinical studies and associated regulatory interactions with health authorities. "
https://www.prnewswire.com/news-releases/soligenix-announces-formation-of-behcets-disease-medical-advisory-board-302057074.html